DPYD Pharmacogenetics: To Opt-in or to Opt-out.

The article comments on a study by J. O. Jacobson and colleagues on a method to integrate dihydropyrimidine dehydrogenase (DPYD) test into the clinics at the Dana Farber Cancer Institute. Topics mentioned include the role of pharmacogenetics in enhancing care and reducing medical care cost, the effectiveness of 5-fluorouracil and fluoropyrimidine prodrug capecitabine in combination with oxaliplatin for the management of colon and rectal cancers and the complexity of DPYD genetics.